PDCD1 and neoplasm: In our pre-clinical mouse model, we also found that sirolimus could reduce irAEs and increase ICD in the tumor microenvironment, which further accelerates the anti-tumor immune responses and so synergizes with anti-PD-1 to decrease tumor progression.